$RGC

Regencell reported a net loss of $11.7M for fiscal 2026, up from $3.58M in 2025, with no revenue from product sales. Its TCM formula candidates for ADHD and autism are still in development, and it faces ongoing DOJ investigations into its stock trading. The company expects increasing losses and may need additional financing.

The article is a press-release style notice in which Rosen and National Trial Lawyers encourage investors to consider legal action related to Regencell Bioscience Holdings. It does not provide specific allegations, financial figures, or case details. The notice directs questions to the company named in the release and states PR-inside is not responsible for the content.

Regencell Bioscience Holdings (NASDAQ:RGC) shares fell 5.1% on Tuesday, trading between $24.30 and $24.48 versus a prior close of $25.80. Volume was 100,662 shares, down 67% from average. Weiss Ratings reiterated a “sell (e+)” rating. The company reported $0.00 EPS in its May 8 quarter.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Regencell made false and misleading statements about the company's operations, business, and compliance policies, leading to market manipulation and significant financial risk for investors. Investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, are encouraged to join the case, with a lead plaintiff deadline of June 23, 2026.

The Rosen Law Firm announces a class action lawsuit against Regencell Bioscience Holdings Limited (NASDAQ: RGC) for investors who purchased securities between October 28, 2024, and October 31, 2025. The lawsuit alleges that Regencell made false and misleading statements, exposing investors to significant financial risk and market manipulation. Investors are encouraged to secure counsel before the June 23, 2026, deadline to serve as lead plaintiff.

U.S. stock indexes closed mixed on Thursday, with the S&P 500 up 0.18%, the Dow Jones Industrial Average rising 0.11%, and the Nasdaq Composite falling 0.13%. Communications stocks performed well, while Regencell Bioscience lagged.

Regencell Bioscience Holdings (RGC) has seen a significant 50% stock surge this week, rekindling investor interest despite its volatile history. The company, known for extreme price swings disconnected from fundamental value, faces regulatory scrutiny from the U.S. Department of Justice and a "going concern" warning due to its early-stage financial position and lack of commercialized products. Despite a $24 billion market cap, its future depends on securing additional funding amidst ongoing speculation.

Regencell Bioscience Holdings (RGC) has filed for a US$500 million at-the-market offering, highlighting potential dilution for shareholders. Despite a significant one-year return, the stock has recently declined, and its Price-to-Book ratio of 2,373.6x is substantially higher than industry and peer averages, indicating a focus on future potential rather than current financial performance, as the company operates with no revenue and ongoing losses. This high valuation, coupled with the lack of revenue and losses, suggests the stock could be vulnerable to setbacks.

Regencell Bioscience Holdings (RGC) has experienced significant share price volatility, including a 151.81% return in 7 days, amidst a U.S. Department of Justice trading investigation. Despite virtually no revenue and recent losses, the company trades at an extremely high price-to-book ratio of 5,380.1x, far exceeding industry averages. This valuation raises questions about investor expectations, with Simply Wall St deeming the stock overvalued and highlighting the risks associated with zero revenue and the ongoing investigation.

Is the stock likely to keep surging? The answer seems pretty clear.